Company news
Edwards Lifesciences Corporation news in 2025
Edwards Lifesciences Corporation's news releases, calls and decks from 2025, newest first.
FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy
December 23, 2025
Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference
December 4, 2025
Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease
November 9, 2025
Edwards Lifesciences Announces CFO Transition Plan
October 30, 2025
Edwards Lifesciences Reports Third Quarter Results
October 30, 2025
Successful Patient Outcomes Demonstrated With Edwards’ SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025
October 27, 2025
Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025
October 27, 2025
Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025
October 23, 2025
Updated ESC/EACTS Guidelines Mark Advancement in Structural Heart Disease Care
August 29, 2025
Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer
August 25, 2025
Edwards Lifesciences Announces $500 Million Accelerated Share Repurchase
August 19, 2025
Edwards Lifesciences Comments on FTC’s Action to Block Proposed Acquisition of JenaValve
August 6, 2025
Edwards Lifesciences Reports Second Quarter Results
July 24, 2025
Edwards Lifesciences to Host Earnings Conference Call on July 24, 2025
July 18, 2025
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
May 22, 2025
Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference
May 6, 2025
Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis
May 1, 2025
Edwards Lifesciences Reports First Quarter Results
April 23, 2025
Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue
April 18, 2025
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025
April 16, 2025
Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System
April 14, 2025
New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients
March 31, 2025
Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference
February 25, 2025
Calls in 2025
Decks in 2025
- Investor Day (December 2025)
Investor day · 139 slides · Dec 4, 2025
- Shareholder Meeting (March 2025)
Shareholder meeting · 13 slides · Mar 26, 2025